Press Releases

Wistar’s Cancer Center became the first National Cancer Institute-designated basic cancer center in the nation in 1972 and has held this national recognition for the past 46 years.

PHILADELPHIA — (April 18, 2019) — Wistar scientists have developed a novel synthetic DNA approach for patient-specific production of cancer-targeting molecules called bispecific T cell engagers. DNA-encoded bispecific T cell engagers (dBiTEs) designed against the HER2 protein were tested in preclinical models of ovarian cancer and induced tumor regression, demonstrating the potential of this novel approach for immunotherapy. Study results were published online in JCI Insights. 

Pharmacological block of the FATP2 protein selectively inhibits myeloid-derived suppressor cells and shows antitumor effects in preclinical models.

The DNA-encoded monoclonal antibody platform provides rapid and sustained protection against Zika virus infection.

First-in-class pharmacological inhibitors of the EBNA1 viral protein are effective at inhibiting tumor growth in preclinical models.